@article{f8a310ee05544e628da2ba04b80cebae,
title = "The St. George's Respiratory Questionnaire Appendix to the Food and Drug Administration Draft Guidance on COPD: Why a Small Step Forward Is So Important",
author = "Rennard, {Stephen I.} and Debora Merrill and Ruth Tal-Singer and Sciurba, {Frank C.}",
note = "Funding Information: FINANCIAL/NONFINANCIAL DISCLOSURES: The authors have reported to CHEST the following: S. I. R. is employed by AstraZeneca, Cambridge, England, and also retains professorship and a part-time appointment at the University of Nebraska Medical Center, Omaha, Nebraska. Over the last year, S. I. R. reports personal fees from the Japanese Thoracic Society, personal fees from Tokyo University, and grants from National Heart, Lung, and Blood Institute. Since August 2015, S. I. R. has been an employee of AstraZeneca and owns shares in the company. D. M. works as a consultant to the COPD Foundation, managing the COPD Biomarker Qualification Consortium. The goals of the consortium are to select biomarkers of interest for COPD clinical trials, and aggregate data from multiple sources (pharma companies, academic research, and government sources) as appropriate, and analyze the data to support regulatory qualification packages. The consortium is funded through membership and data management fees, contributed by the participating companies. R. T.-S. is an employee and shareholder of GSK. None declared (F. C. S.). ",
year = "2017",
month = nov,
doi = "10.1016/j.chest.2017.07.040",
language = "English (US)",
volume = "152",
pages = "914--916",
journal = "Chest",
issn = "0012-3692",
publisher = "Elsevier Inc.",
number = "5",
}